Table 1. Demographic and clinical characteristics in the dengue and nondengue groups.
Dengue cohort (N = 13267) | Nondengue cohort (N = 53068) | χ2 p-value | Standardized difference | |
---|---|---|---|---|
Sex | ||||
Female | 6701 (50.5) | 26804 (50.5) | - | |
Male | 6566 (49.5) | 26264 (49.5) | - | |
Age (years) | 44.4 (18.6) * | 44.4 (18.6) * | - | |
0–17 | 1279 (9.7) | 5116 (9.7) | - | |
18–35 | 3055 (23.0) | 12220 (23.0) | - | |
36–50 | 3436 (25.9) | 13744 (25.9) | - | |
51–64 | 3616 (27.3) | 14464 (27.3) | - | |
≥65 | 1881 (14.2) | 7524 (14.2) | - | |
Area of residence | ||||
Tainan | 2875 (21.7) | 11500 (21.7) | - | |
Kaohsiung | 8668 (65.3) | 34672 (65.3) | - | |
Pingtung | 642 (4.8) | 2568 (4.8) | - | |
Others | 1082 (8.2) | 4328 (8.2) | - | |
Comorbidity | ||||
Hypertension | 2759 (20.8) | 9778 (18.4) | <.0001 | 0.061 |
Diabetes mellitus | 1351 (10.2) | 4687 (8.8) | <.0001 | 0.047 |
Coronary artery disease | 1136 (8.6) | 3618 (6.8) | <.0001 | 0.067 |
COPD | 732 (5.5) | 2747 (5.2) | 0.115 | 0.015 |
Chronic renal disease | 334 (2.5) | 1207 (2.3) | 0.096 | 0.016 |
Liver cirrhosis | 65 (0.5) | 279 (0.5) | 0.608 | 0.005 |
Uncomplicated PUD | 1341 (10.1) | 4681 (8.8) | <.0001 | 0.045 |
Dyslipidemia | 1704 (12.8) | 5514 (10.4) | <.0001 | 0.079 |
Ischemic stroke | 280 (2.1) | 1128 (2 1) | 0.914 | 0.001 |
Medication | ||||
Acetylsalicylic acid | 829 (6.3) | 2598 (4.9) | <.0001 | 0.061 |
NSAIDs | 7385 (55.7) | 24162 (45.5) | <.0001 | 0.204 |
Steroids | 2010 (15.2) | 6804 (12.8) | <.0001 | 0.069 |
Thienopyridine | 96 (0.7) | 284 (0.5) | 0.010 | 0.025 |
Dipyridamole | 365 (2.8) | 1135 (2.1) | <.0001 | 0.041 |
Anticoagulants | 38 (0.3) | 140 (0.3) | 0.653 | 0.004 |
SSRIs | 142 (1.1) | 534 (1.0) | 0.511 | 0.006 |
Data are expressed in number and percentage, except for the variable “age,” of which the *mean and standard deviation are also shown.
COPD = chronic obstructive pulmonary disease.
NSAIDs = nonsteroidal anti-inflammatory drugs
SSRIs = selective serotonin reuptake inhibitors
PUD = peptie ulcer disease